Lab Spotlight –
Bristol Myers Squibb

Improve your modeling power with the SomaScan® 11K Assay (11,000 total protein measurements)

Pioneering Precision: Unlocking Deeper Insights with 11K Total Protein Measurements

Peter Schafer and Fred Baribaud, scientists from Bristol Myers Squibb, explain how 11K total protein measurements deliver on more data points, allowing them to identify true patterns and their association with clinical outcomes.

Download the transcript, or read on-screen by clicking “Read the transcript” below

Read the transcript

PETER SCHAFER (00;00;01;05 – 00;00;12;09)
Over the past couple of decades, you can only measure, you know, 10 or 20 proteins at a time. Now we’re finally catching up, I think, to the genomics and the transcriptomics.

PETER SCHAFER (00;00;16;23 – 00;00;29;02)
My name is Peter Schafer. I am Scientific Vice President for translational medicine at Bristol Myers Squibb, and my team works on the late clinical stage assets in immunology, cardiovascular, and neuroscience.

FRED BARIBAUD (00;00;29;02 – 00;00;55;00)
We use proteomics as one of our data dimensions to do three fundamental things. One is to inform us on pharmacodynamics effects of our therapeutics. Another one is to understand the diversity of the patients we treat with their various levels of response. And the third one really is around understanding better the diseases themselves and what the driving disease mechanisms are.

PETER SCHAFER (00;00;55;00 – 00;01;06;01)
So we’ve been working with SomaScan platform for several years. I’ve been really impressed by the ability to discover those novel biomarkers that you wouldn’t necessarily expect.

FRED BARIBAUD (00;01;06;01 – 00;01;27;05)
I think the development of a SomaLogic platform and its migration from 3 to 5 to 7 and now to 11K makes usage of proteomics more affordable, but also delivers on more data points. And I think that’s a fundamental evolution we have seen over the past 10 or 15 years,

PETER SCHAFER (00;01;27;05 – 00;01;58;18)
My impression of the 11K Assay is that it greatly expands the markers that are available in several therapeutic areas, and that includes immunology, cardiovascular disease, neuroscience and oncology. I’m just thrilled that we finally have these broad, proteomic platforms, because we’ve been looking for individual biomarkers, but when you have such a broad platform for 11,000, you can find sets of biomarkers and this greatly improves the power to model what you’re trying to predict or prognosis.

FRED BARIBAUD (00;01;58;18 – 00;02;24;18)
I think we’ll have the possibility of a fundamental change where some of your daily health care as an individual who suffers from a chronic disease is put in your hands and can be monitored with the help of SomaLogic platforms, for example, and we’ll probably put more responsibility in every patient and more information. I think that’s key going forward.

PETER SCHAFER (00;02;24;18 – 00;02;47;28)
Now we’re finally getting to the point where we can do very broad proteomics studies. And that is fantastic because now we can start combining those data sets together and seeing what the true patterns are and associate it with the clinical outcomes. So very exciting time. The more that we can do to identify the right drug for the right patient at the right time, the better off everybody will be.

Learn more about the SomaScan® 11K Assay, now covering half of the genetically encoded human proteome

Learn more

Read the SomaScan® 11K Assay technical note for platform background and performance metrics

Read the tech note